Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2000
05/31/2000CN1255141A Salts of 5 'alpha'-pregn-16-en-3 'beta'-ol-20-one 3-sulphate ester with progestin activity
05/31/2000CN1255135A New class of benzoporphyrin derivative photoactive compounds
05/31/2000CN1255121A Selective epoxidation process for preparing pharmaceutical compounds
05/31/2000CN1255061A Use of chelerythrine and radiation for tumor therapy
05/31/2000CN1255056A Intravaginal drug delivery devices for idminsitration of testosterone and testosterone precursors
05/31/2000CN1255041A Methods and compositions for treatment of aids-associated kaposi's sarcoma
05/31/2000CN1254715A Isoesperamicin and its synthesizing process and usage
05/31/2000CN1254595A Gene activity paste for treating cancer
05/31/2000CN1254591A Dual-phase anticancer capsule
05/31/2000CN1254581A Chinese patent medicine for treating cancers and unknown toxic swellings (subcutaneous ulcer and carbuncle) and its preparing process
05/31/2000CN1254561A Anticancer goose blood preparation
05/31/2000CN1052904C Injection for curing cancer
05/31/2000CN1052878C Buffer choline phosphorus aqueous solution and its preparation method, medicine and usage
05/30/2000US6069283 Illudin analogs useful as antitumor agents
05/30/2000US6069260 Stereospecific taxane derivative having metal salt of the hydroxy attached to the carbon at the 13 ring position; chemical intermediates for antitumor agents
05/30/2000US6069242 Mixture of pharmaceutically acceptable carrier and antisense nucleic acid; for diagnosis, imaging, anticarcinogenic agents, antitumor agents
05/30/2000US6069231 Amino acid sequences of domains found in transcription factors including a mammalian retinoblastoma-interacting zinc finger protein; for fusion proteins useful for regulating transcription of target genes; diagnosis of related diseases
05/30/2000US6069174 Protein kinase C activators and their use in increasing expression of cell antigens
05/30/2000US6069158 10,11-dihydro-3(3-(4-amino-2-pyridylamino)-1-propyloxy)-5h-dib enzo(a,d)cycloheptene-10-acetic acid
05/30/2000US6069150 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
05/30/2000US6069146 Halimide, a cytotoxic marine natural product, and derivatives thereof
05/30/2000US6069140 Pharmaceutical compositions comprising texaphyrins
05/30/2000US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
05/30/2000US6069134 Methods and compositions comprising DNA damaging agents and p53
05/30/2000US6069127 Human infant formula containing a glycoprotein specific for binding to the human mac-2 (macrophage antigen) lectin; to prevent infections
05/30/2000US6069006 Connective tissue growth factor (CTGF) regulatory nucleic acid sequences
05/30/2000US6069001 Nucleotide sequence; for use in diagnosis of cancer and melanoma; for use in human leukocyte antigen typing for grafts and transplants
05/30/2000US6068984 Separating hb15 prositive cells from population of unrelated cells by reacting antibody that specifically binds the extracellular, transmembrane or cytoplasmic domain of the glycoprotein, then isolating cells
05/30/2000US6068851 Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
05/30/2000US6068850 A stable aqueous formulation of a peptide related compound comprising atleast one peptide compoun and water, wherein the formulation is stable at 37 degree c. atleast 2 months, useful in an implantable drug delivery device
05/30/2000US6068845 Inhibitory activity on the abnormal production of extracellular matrices in dermal fibroblasts activated with tranforming growth factor beta by administering the plant extract of a plant belonging to the genus sophora
05/30/2000US6068837 Mesothelial cell gene therapy
05/30/2000CA2206104C Adamantyl substituted oxindoles as pharmaceuticals agents
05/30/2000CA2182707C 3'-substituted nucleoside derivative
05/30/2000CA2181566C Compositions and methods using unbound mpl receptor for stimulating platelet production
05/25/2000WO2000029623A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
05/25/2000WO2000029609A1 N-terminally truncated her-2/neu protein as a cancer prognostic indicator
05/25/2000WO2000029600A1 Systemic viral/ligand gene delivery system and gene therapy
05/25/2000WO2000029599A1 Viral vectors with late transgene expression
05/25/2000WO2000029584A1 Antibody variants with higher binding affinity compared to parent antibodies
05/25/2000WO2000029583A2 Immunoglobulin superfamily proteins
05/25/2000WO2000029581A1 Human tslp dna and polypeptides
05/25/2000WO2000029580A1 Calcium binding protein
05/25/2000WO2000029578A1 Cloning and characterization of two m-rna transcription factors
05/25/2000WO2000029573A2 Adenoviral vectors
05/25/2000WO2000029551A2 Cells, culture methods, and their use in autologous transplantation therapy
05/25/2000WO2000029501A1 Radioactive coating solutions, methods, and substrates
05/25/2000WO2000029447A1 Rhamm antagonist antibodies
05/25/2000WO2000029438A1 Egf-like nucleic acids and polypeptides and uses thereof
05/25/2000WO2000029435A1 12 human secreted proteins
05/25/2000WO2000029428A2 5t4 tumour-associated antigen for use in tumour immunotherapy
05/25/2000WO2000029422A1 31 human secreted proteins
05/25/2000WO2000029405A1 Method for preparing (2s)-1-[ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide
05/25/2000WO2000029401A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/25/2000WO2000029384A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
05/25/2000WO2000029382A1 Certain substituted caprolactams, pharmaceutical compositions containing them and their use in treating tumors
05/25/2000WO2000029376A1 Heteroarylthio compounds and cancer remedies containing the same
05/25/2000WO2000029375A1 Bisaryl compounds and cancer remedies containing the same
05/25/2000WO2000029033A2 A method of genetic vector delivery
05/25/2000WO2000029029A1 Compositions and methods for producing vascular occlusion
05/25/2000WO2000029025A1 Stable amorphous amifostine compositions and methods for the preparation and use of same
05/25/2000WO2000029020A1 Anti-icam-r antibody-induced apoptosis
05/25/2000WO2000029015A2 INFLUENCING OF ANGIGENESIS USING CD66a
05/25/2000WO2000029012A2 Methods of alleviating cancer symptoms
05/25/2000WO2000029011A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
05/25/2000WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives
05/25/2000WO2000028975A2 Improved chemical process and pharmaceutical formulation
05/25/2000WO2000028971A1 Nano-emulsion of 5-aminolevulinic acid
05/25/2000WO2000018385A3 Use of acylcarnitines as antitumour agents
05/25/2000WO2000015788A3 Dna sequence encoding oncofetal ferritin protein
05/25/2000WO2000015247A3 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
05/25/2000WO2000015209A3 REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES
05/25/2000WO2000014228A8 Neutral amino acid transporter and gene thereof
05/25/2000WO2000012111A3 Selective treatment of endothelial somatostatin receptors
05/25/2000WO2000008495A3 Antiproliferative naphthoquinones, derivatives, compositions, and uses thereof
05/25/2000WO2000000825A9 Detection and modulation of cellular immunity to immune privileged antigens
05/25/2000WO1999053949A9 Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy
05/25/2000DE19853066A1 Use of hyaluronic acid fragments in vaccine production, especially for cancer treatment
05/25/2000DE19850986A1 Die gentechnische Prägung von Zellen und ihre Verwendung zur Prophylaxe und Therapie von Erkrankungen The genetic imprint of cells and their use in the prophylaxis and treatment of diseases
05/25/2000CA2351622A1 Polypeptide
05/25/2000CA2351585A1 Influencing of angigenesis using cd66a
05/25/2000CA2351576A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
05/25/2000CA2351524A1 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumour vaccines
05/25/2000CA2351522A1 Egf-like nucleic acids and polypeptides and uses thereof
05/25/2000CA2351187A1 Tetrahydroisoquinoline derivatives as lhrh antagonists
05/25/2000CA2350914A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
05/25/2000CA2350785A1 31 human secreted proteins
05/25/2000CA2350389A1 Calcium binding protein
05/25/2000CA2349762A1 Human tslp dna and polypeptides
05/25/2000CA2349581A1 Anti-icam-r antibody-induced apoptosis
05/25/2000CA2349238A1 Systemic viral/ligand gene delivery system and gene therapy
05/25/2000CA2348824A1 12 human secreted proteins
05/25/2000CA2348781A1 Compositions and methods for producing vascular occlusion
05/25/2000CA2348676A1 Method for preparing (2s)-1-¬ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl| pyrrolidine-2- carboxamide
05/25/2000CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/25/2000CA2347833A1 Antibody variants with higher binding affinity compared to parent antibodies
05/24/2000EP1002799A1 Optically pure androgen mediator
05/24/2000EP1002556A2 Use of MMP inhibitors
05/24/2000EP1002543A1 Pharmaceutical compositions for the therapy of glioma or prostate cell proliferative disorders containing cyclic rgd compounds
05/24/2000EP1002535A1 New use of glutamate antagonists for the treatment of cancer
1 ... 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 ... 2211